MX2022012676A - Compuestos y metodos para modular el empalme. - Google Patents

Compuestos y metodos para modular el empalme.

Info

Publication number
MX2022012676A
MX2022012676A MX2022012676A MX2022012676A MX2022012676A MX 2022012676 A MX2022012676 A MX 2022012676A MX 2022012676 A MX2022012676 A MX 2022012676A MX 2022012676 A MX2022012676 A MX 2022012676A MX 2022012676 A MX2022012676 A MX 2022012676A
Authority
MX
Mexico
Prior art keywords
methods
compounds
splicing
modulating splicing
modulating
Prior art date
Application number
MX2022012676A
Other languages
English (en)
Inventor
Peter Smith
Dominic Reynolds
Serge Leger
Michael W Seiler
Anant A Agrawal
Frederic Vaillancourt
Original Assignee
Remix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remix Therapeutics Inc filed Critical Remix Therapeutics Inc
Publication of MX2022012676A publication Critical patent/MX2022012676A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Replacement Of Web Rolls (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente divulgación presenta compuestos y composiciones relacionadas que, entre otras cosas, modulan el empalme de ácidos nucleicos, p. ej., el empalme de un pre-ARNm, así como métodos de uso de estos.
MX2022012676A 2020-04-08 2021-04-08 Compuestos y metodos para modular el empalme. MX2022012676A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063007327P 2020-04-08 2020-04-08
US202063043920P 2020-06-25 2020-06-25
US202063072873P 2020-08-31 2020-08-31
US202063126493P 2020-12-16 2020-12-16
PCT/US2021/026435 WO2021207530A1 (en) 2020-04-08 2021-04-08 Compounds and methods for modulating splicing

Publications (1)

Publication Number Publication Date
MX2022012676A true MX2022012676A (es) 2023-01-11

Family

ID=75747105

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022012676A MX2022012676A (es) 2020-04-08 2021-04-08 Compuestos y metodos para modular el empalme.
MX2022012677A MX2022012677A (es) 2020-04-08 2021-04-08 Compuestos y metodos para modular el empalme.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022012677A MX2022012677A (es) 2020-04-08 2021-04-08 Compuestos y metodos para modular el empalme.

Country Status (13)

Country Link
EP (2) EP4132935A1 (es)
JP (2) JP2023520924A (es)
KR (2) KR20230004575A (es)
CN (2) CN116096725A (es)
AU (2) AU2021253571A1 (es)
BR (2) BR112022020337A2 (es)
CA (2) CA3175193A1 (es)
CL (1) CL2022002779A1 (es)
CO (1) CO2022015926A2 (es)
CR (1) CR20220567A (es)
IL (1) IL297149A (es)
MX (2) MX2022012676A (es)
WO (2) WO2021207550A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689863A1 (en) 2017-08-04 2020-08-05 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
EP4149937A1 (en) 2020-05-13 2023-03-22 CHDI Foundation, Inc. Htt modulators for treating huntington's disease
EP4308577A1 (en) * 2021-03-17 2024-01-24 F. Hoffmann-La Roche AG New thiadiazolopyrimidone derivatives
EP4308576A1 (en) * 2021-03-17 2024-01-24 F. Hoffmann-La Roche AG New thiazolopyrimidinone derivatives
TW202330552A (zh) * 2021-10-13 2023-08-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
CA3239110A1 (en) * 2021-11-24 2023-06-01 Dominic Reynolds Compounds and methods for modulating splicing

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
WO2008057601A2 (en) * 2006-11-08 2008-05-15 The Rockefeller University Organic compounds
EP2593106A4 (en) * 2010-07-16 2014-01-01 Univ Rockefeller ORGANIC CONNECTIONS
JP6092897B2 (ja) 2012-02-10 2017-03-08 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
WO2016128343A1 (en) 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
EP3515919A1 (de) * 2016-09-23 2019-07-31 Bayer Aktiengesellschaft N3-cyclisch substituierte thienouracile und ihre verwendung
CA3043755A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc. Methods for modulating rna splicing
CA3065547A1 (en) 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
CA3066939A1 (en) * 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3689863A1 (en) 2017-08-04 2020-08-05 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN111373057A (zh) 2017-09-25 2020-07-03 斯基霍克疗法公司 用于筛选和鉴定剪接调节剂的方法和组合物
KR20200142039A (ko) 2018-04-10 2020-12-21 스카이호크 테라퓨틱스, 인코포레이티드 암 치료용 화합물
EP3816160A4 (en) * 2018-06-27 2022-03-16 Reborna Biosciences, Inc. PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY

Also Published As

Publication number Publication date
CN116096725A (zh) 2023-05-09
BR112022020337A2 (pt) 2022-12-13
JP2023520925A (ja) 2023-05-22
MX2022012677A (es) 2023-01-11
AU2021251220A1 (en) 2022-11-03
AU2021253571A1 (en) 2022-11-10
CN116134036A (zh) 2023-05-16
JP2023520924A (ja) 2023-05-22
KR20230004575A (ko) 2023-01-06
WO2021207550A1 (en) 2021-10-14
CO2022015926A2 (es) 2022-11-29
WO2021207530A1 (en) 2021-10-14
EP4132935A1 (en) 2023-02-15
CA3175193A1 (en) 2021-10-14
IL297149A (en) 2022-12-01
EP4132936A1 (en) 2023-02-15
CR20220567A (es) 2023-01-13
KR20230005210A (ko) 2023-01-09
CA3175205A1 (en) 2021-10-14
BR112022020418A2 (pt) 2023-05-02
CL2022002779A1 (es) 2023-04-28
WO2021207530A8 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
MX2022010683A (es) Compuestos y metodos para modular el empalme.
MX2022012676A (es) Compuestos y metodos para modular el empalme.
MX2022012678A (es) Compuestos y metodos para modular el corte y empalme.
MX2022010637A (es) Derivados de piridazina para modular el empalme de acidos nucleicos.
MX2022010681A (es) Compuestos y metodos para modular el empalme.
MY201938A (en) Methods and compositions for modulating splicing
MX2020006072A (es) Métodos y composiciones relacionados con cpf1 para la edición genica.
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
CR20220351A (es) Inhibidores de proteínas kras mutantes
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
PH12020550524A1 (en) Modulators of the integrated stress pathway
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2020007812A (es) Moduladores del receptor de quimiocina y usos de los mismos.
MX2022003166A (es) Moduladores de il-17a y usos de los mismos.
PH12020551327A1 (en) Compounds
WO2011100374A3 (en) Mediator and cohesin connect gene expression and chromatin architecture
MX2020007531A (es) Aminopirrolotriazinas como inhibidores de cinasa.
MX2020012765A (es) Métodos y compuestos de ácido nucleico modificado con lípidos.
MX2021002617A (es) Indazol carboxamidas como inhibidores de cinasas.
MX2023001558A (es) Composiciones para modular el corte y empalme.
MX2022015284A (es) Composiciones y metodos para la edicion del epigenoma.
MX2022014126A (es) Moduladores de enpp1 y usos de los mismos.
CR20220483A (es) Compuestos y métodos para modular el empalme
AU2018275786A1 (en) Method for dispersing kinetic hydrate inhibitors
CU20220019A7 (es) Proteínas de fusión nkg2d